Grace Therapeutics, Inc GRCE

Healthcare

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.

NDAQ:GRCE - Post by User

Grace Therapeutics, Inc

Bullboard Posts

Comment by postie1on Feb 13, 2020 2:55pm

117 Views

Post# 30687394

RE:RE:RE:RE:FYI - George W. Haywood - SCHEDULE 13G - February 13, 2020

Question is, when did he sell?

"February 13, 2020 - Haywood George Weaver has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 1,801,831 shares of Acasti Pharma, Inc. (NASDAQ:ACST). This represents 2.1 percent ownership of the company. In their previous filing dated February 13, 2019, Haywood George Weaver had reported owning 7,396,906 shares, indicating a decrease of -75.64 percent."

Bullboard Posts

AI companies to invest in